RE:RE:RE:moving on up...........................What's happening with your production jobs? When will this hit $50 easy, pumper? This thing is in death spiral and you are here pumping all day long with 5 boardnames. That's just evil and sick, dude. All the analysts lowered their price targets and will not change again until something
meaningful happens and the MAD study will be reported as not as good as expected and any chance of 4050 being commercialized by Liminal will be gone. Money means salaries for management and that's it unless they have some other Milestones. And they cancelled IPF and hypertriglyceridemia phase 2 trials.
captsecord wrote: with that much cash on hand, we can wait for the news, this stock will swing huge from a market cap of 75M$. I'm expecte analysts to cover this. And when u see spammers like this after your shares, you do what they do...buy. Pbi4050 is listed on the NR as well,
Mariadelapena wrote:
I'm patient, and accumulating as well. Cant wait for the next news like operations update or an analyst review, at a market cap of 75M$, this will move up several fold easy!
captsecord wrote:
market cap 75M$, plenty of cash for nearly 2 years. ALL going as best it can go. Pipeline is good, money is good, sp is extremely cheap... i'm glad im loaded!!!!
Key Corporate and R&D Priorities
- Upon closing of sale of the Rare Pediatric Disease Priority Review Voucher ("PRV") for US$105 million, Liminal will be entitled to receive an amount equal to 70% of the net proceeds, which would be payable to Liminal by its subsidiary Prometic Biotherapeutics Inc. ("PBT") prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT to Kedrion S.p.A. ("Kedrion").
- Pending full analysis of the complete PK data set from the phase 1 multi-ascending dose ("MAD") clinical trial, we intend to determine the choice of other potential indication(s) for further development of fezagepras. No dose-limiting adverse events or other potential safety signals have been observed in the phase 1 MAD clinical trial to date.
- Pending the outcome of our pre-clinical research, and successful nomination of a pre-clinical drug candidate, we plan to initiate a pre-clinical Investigational New Drug ("IND") enabling program to support a first-in-human Phase 1 single-ascending dose clinical trial of our GPR84 antagonist drug candidate to be selected in healthy volunteers for safety and tolerability.
- Pending the outcome of our pre-clinical research, and successful nomination of a pre-clinical drug candidate, we plan to initiate a pre-clinical IND enabling program to support a first-in-human Phase 1 single-ascending dose clinical trial of our OXER1 drug candidate to be selected in healthy volunteers for safety and tolerability.
Newcamo wrote: market cap 75M$.... cash on hand 140M$.....full pipeline + full of spammers that want your shares and are buying.....